Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 401

1.

A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.

Heald AH, Knapman H, Nair S, Chambers T, Radford D, Rushton T, Anderson SG.

Prim Care Diabetes. 2012 Oct;6(3):213-9. doi: 10.1016/j.pcd.2012.02.002. Epub 2012 May 4.

PMID:
22560663
2.

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

Hermann LS, Ranstam J, Vaaler S, Melander A.

Diabetes Obes Metab. 1999 Jul;1(4):227-32.

PMID:
11228758
3.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
4.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
5.

Change in cardiovascular risk factors in relation to diabetes status: the Tromso Study.

Joseph J, Svartberg J, Njølstad I, Schirmer H.

Eur J Prev Cardiol. 2012 Jun;19(3):551-7. doi: 10.1177/1741826711408147. Epub 2011 Apr 19.

PMID:
21505026
6.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group..

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

7.
9.

Type 1 diabetes in Cheshire: cardiometabolic risk factor trends (2004-2009).

Anderson SG, Narayanan RP, Amlesh J, Qureshi MZ, Heald AH.

Prim Care Diabetes. 2012 Jul;6(2):123-6. doi: 10.1016/j.pcd.2011.10.007. Epub 2011 Dec 3.

PMID:
22137766
10.

Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.

Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA.

Diabetes Metab. 2009 Nov;35(5):385-91. doi: 10.1016/j.diabet.2009.03.005. Epub 2009 Aug 7.

PMID:
19665415
11.

Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.

Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.

Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47. Epub 2005 Oct 20.

PMID:
16487914
12.

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.

Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM.

Metabolism. 2004 Feb;53(2):159-64.

PMID:
14767866
13.

Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.

Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB; Diabetes Prevention Program Research Group..

Diabetes Obes Metab. 2014 Apr;16(4):326-33. doi: 10.1111/dom.12220. Epub 2013 Oct 29.

14.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
15.

[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].

Vanuzzo D, Pilotto L, Mirolo R, Pirelli S.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. Review. Italian.

PMID:
18773746
16.

Egg consumption as part of an energy-restricted high-protein diet improves blood lipid and blood glucose profiles in individuals with type 2 diabetes.

Pearce KL, Clifton PM, Noakes M.

Br J Nutr. 2011 Feb;105(4):584-92. doi: 10.1017/S0007114510003983. Epub 2010 Dec 7.

PMID:
21134328
17.

Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community.

Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, Mirmiran P, Azizi F.

Am J Prev Med. 2010 Jun;38(6):628-636.e1. doi: 10.1016/j.amepre.2010.03.003.

PMID:
20494239
19.

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.

Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT.

J Intern Med. 2004 Jul;256(1):1-14. Review.

20.

The relationship between socioeconomic deprivation and metabolic/cardiovascular risk factors in a cohort of patients with type 2 diabetes mellitus.

O'Kane MJ, McMenamin M, Bunting BP, Moore A, Coates VE.

Prim Care Diabetes. 2010 Dec;4(4):241-9. doi: 10.1016/j.pcd.2010.08.004.

PMID:
20869343

Supplemental Content

Support Center